MX2024008821A - Formas solidas cristalinas de inhibidores de la helicasa-primasa y proceso de preparacion de las mismas. - Google Patents

Formas solidas cristalinas de inhibidores de la helicasa-primasa y proceso de preparacion de las mismas.

Info

Publication number
MX2024008821A
MX2024008821A MX2024008821A MX2024008821A MX2024008821A MX 2024008821 A MX2024008821 A MX 2024008821A MX 2024008821 A MX2024008821 A MX 2024008821A MX 2024008821 A MX2024008821 A MX 2024008821A MX 2024008821 A MX2024008821 A MX 2024008821A
Authority
MX
Mexico
Prior art keywords
helicase
crystalline forms
solid crystalline
preparation
primase inhibitors
Prior art date
Application number
MX2024008821A
Other languages
English (en)
Spanish (es)
Inventor
Christian Gege
Gerald Kleymann
Original Assignee
Innovative Molecules Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Molecules Gmbh filed Critical Innovative Molecules Gmbh
Publication of MX2024008821A publication Critical patent/MX2024008821A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024008821A 2022-01-17 2023-01-16 Formas solidas cristalinas de inhibidores de la helicasa-primasa y proceso de preparacion de las mismas. MX2024008821A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22151820 2022-01-17
EP22170332 2022-04-27
PCT/EP2023/050883 WO2023135303A1 (en) 2022-01-17 2023-01-16 Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof

Publications (1)

Publication Number Publication Date
MX2024008821A true MX2024008821A (es) 2024-07-29

Family

ID=84982261

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008821A MX2024008821A (es) 2022-01-17 2023-01-16 Formas solidas cristalinas de inhibidores de la helicasa-primasa y proceso de preparacion de las mismas.

Country Status (12)

Country Link
US (1) US20250115565A1 (cg-RX-API-DMAC10.html)
EP (1) EP4466255A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025502300A (cg-RX-API-DMAC10.html)
KR (1) KR20240134979A (cg-RX-API-DMAC10.html)
AU (1) AU2023206628A1 (cg-RX-API-DMAC10.html)
CA (1) CA3246779A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024002124A1 (cg-RX-API-DMAC10.html)
IL (1) IL314188A (cg-RX-API-DMAC10.html)
MX (1) MX2024008821A (cg-RX-API-DMAC10.html)
PY (1) PY2302301A (cg-RX-API-DMAC10.html)
UY (1) UY40111A (cg-RX-API-DMAC10.html)
WO (1) WO2023135303A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4580601A1 (en) * 2022-08-29 2025-07-09 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
IL325911A (en) 2023-07-17 2026-03-01 Innovative Molecules Gmbh Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds
WO2026078039A1 (en) 2024-10-09 2026-04-16 Innovative Molecules Gmbh Oral administration forms of antiviral helicase-primase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
PH12018501979B1 (en) 2016-04-06 2023-05-05 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
PL3692039T3 (pl) 2017-10-05 2023-04-17 Innovative Molecules Gmbh Enancjomery podstawionych tiazoli jako związki przeciwwirusowe
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
AU2021367976A1 (en) 2020-10-29 2023-06-08 Innovative Molecules Gmbh Deuterated aminothiazole compounds as antiviral compounds

Also Published As

Publication number Publication date
CL2024002124A1 (es) 2024-11-22
IL314188A (en) 2024-09-01
UY40111A (es) 2023-08-15
PY2302301A (es) 2023-10-31
US20250115565A1 (en) 2025-04-10
WO2023135303A1 (en) 2023-07-20
CA3246779A1 (en) 2023-07-20
TW202337444A (zh) 2023-10-01
EP4466255A1 (en) 2024-11-27
KR20240134979A (ko) 2024-09-10
AU2023206628A1 (en) 2024-08-01
JP2025502300A (ja) 2025-01-24

Similar Documents

Publication Publication Date Title
ZA202403388B (en) Small molecules for treatement of cancer
CR20230261A (es) Cocristal de un inhibidor de cdk
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
EP4374858A3 (en) Benzimidazolone derived inhibitors of bcl6
CR20230382A (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
TNSN06228A1 (en) Compounds and methods of use
WO2023205463A8 (en) Heteroaryl compounds for the treatment of pain
ZA202208541B (en) Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof
MX2025006384A (es) Formas cristalinas de un inhibidor de trpc de piridazinona
UY40111A (es) Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas
JOP20250051A1 (ar) مُعدِّلات مضاد تربسين ألفا-1
IL172419A0 (en) Piperazine derivatives and methods of use
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
WO2023196720A3 (en) Lrrk2 inhibitors
EP4480538A3 (en) Solid state forms of mavacamten and process for preparation thereof
WO2024006292A3 (en) Methods of treating cancer
WO2024023262A3 (en) Nucleic acid compounds
WO2024026483A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026479A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026486A3 (en) Cdk2 inhibitors and methods of using the same
MX2024015077A (es) Benzopirimidina-4(3h)-onas como inhibidores de pi3k
MX2026000476A (es) Sales clorhidrato cristalinas micronizadas de compuestos inhibidores antiviricos de la helicasa-primasa
MX2025014397A (es) Inhibidores de helicasa de adn recq del sindrome de werner (wrn)